Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for CSBR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
April 30, 2026 -0.019M
January 31, 2026 -0.036M
October 31, 2025 0.168M
July 31, 2025 -0.014M
April 30, 2025 -0.032M
January 31, 2025 0.00
October 31, 2024 0.239M
July 31, 2024 -0.037M
April 30, 2024 -0.145M
January 31, 2024 0.00
October 31, 2023 0.208M
July 31, 2023 -0.59M
April 30, 2023 -0.075M
January 31, 2023 0.00
October 31, 2022 0.086M
July 31, 2022 0.00
April 30, 2022 0.016M
January 31, 2022 0.068M
October 31, 2021 0.121M
July 31, 2021 0.002M
April 30, 2021 0.072M
January 31, 2021 -0.056M
October 31, 2020 1.237M
July 31, 2020 -0.058M
April 30, 2020 4.042M
Date Value
January 31, 2020 0.39M
October 31, 2019 -0.005M
July 31, 2019 -0.007M
April 30, 2019 -0.184M
January 31, 2019 0.351M
October 31, 2018 1.001M
July 31, 2018 0.035M
April 30, 2018 -0.006M
January 31, 2018 0.032M
October 31, 2017 -0.006M
July 31, 2017 -0.007M
April 30, 2017 -0.006M
January 31, 2017 -0.006M
October 31, 2016 -0.021M
July 31, 2016 4.349M
April 30, 2016 0.037M
January 31, 2016 -0.006M
October 31, 2015 -0.004M
July 31, 2015 -0.025M
April 30, 2015 11.21M
January 31, 2015 1.995M
October 31, 2014 0.002M
July 31, 2014 0.00
April 30, 2014 0.021M
January 31, 2014 -0.009M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Medpace Holdings, Inc. -288.34M
Avantor, Inc. -112.40M
Personalis, Inc. 7.988M
Adaptive Biotechnologies Corp. 142.19M
10X Genomics, Inc. 3.016M